$HIMS 20260320 32.0 CALL$ I decided to capitalize on the recent volatility by selling a covered call on HIMS after it gapped up significantly following the announcement of its new partnership with Novo Nordisk. This deal is a major strategic pivot as the company moves toward officially distributing branded Ozempic and Wegovy, which initially sent the share price soaring. However, the stock has since retraced back toward that gap-up level, and I am watching closely to see if it can establish a firm base here. There is a strong possibility it might drift lower to the $19 mark to fully fill the gap before finding a more permanent floor. In the meantime, I will continue to sell covered calls to generate side income and lower my cost basis while I wait for the price to recover and push back above my holding level.